1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,900 | 7,000 | 09.01. | |
| 6,800 | 7,100 | 09.01. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.11.25 | Elicio Therapeutics appoints Marc Wolfgang as chief technology officer | 1 | Investing.com | ||
| 19.11.25 | Elicio Therapeutics Inc.: Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer | 380 | GlobeNewswire (Europe) | BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, "Elicio" or the "Company"), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies... ► Artikel lesen | |
| 13.11.25 | Elicio Therapeutics GAAP EPS of -$0.60 misses by $0.12 | 2 | Seeking Alpha | ||
| ELICIO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 13.11.25 | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates | 165 | GlobeNewswire (Europe) | In the ongoing Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma ("PDAC"), fewer disease progressions and deaths than projected have been observed as... ► Artikel lesen | |
| 07.11.25 | Elicio meldet starke Immunantworten in Phase-2-Studie zu KRAS-Krebsimpfstoff | 1 | Investing.com Deutsch | ||
| 07.11.25 | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC | 194 | GlobeNewswire (Europe) | SITC abstracts highlight updated immunogenicity results from the Phase 2 AMPLIFY-7P trial of ELI-002 7P and preclinical data on the use of intratumoral ELI-004 (AMP-CpG) for solid tumor immunotherapyELI-002... ► Artikel lesen | |
| 27.10.25 | Krebstherapie von Elicio zeigt breite Immunantwort bei diversen HLA-Typen | 1 | Investing.com Deutsch | ||
| 27.10.25 | Elicio's cancer therapy shows immune response across diverse HLA types | 1 | Investing.com | ||
| 18.09.25 | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Inducement Grants | 198 | GlobeNewswire (Europe) | BOSTON, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, "Elicio" or the "Company"), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies... ► Artikel lesen | |
| 17.09.25 | Elicio Reports Strong T Cell Responses In Phase 2 Trial Of Cancer Vaccine | 1 | RTTNews | ||
| 17.09.25 | Elicio: Krebsimpfstoff ELI-002 löst bei 99 % der Patienten starke Immunantwort aus | 2 | Investing.com Deutsch | ||
| 17.09.25 | Elicio's cancer vaccine ELI-002 shows strong immune response in 99% of patients | 2 | Investing.com | ||
| 17.09.25 | Elicio Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.09.25 | Elicio Therapeutics Inc.: Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial | 194 | GlobeNewswire (Europe) | ELI-002 induced mKRAS-specific T cell responses in 99% of evaluable patients (89 of 90) who were treated with the investigational vaccine immunotherapyRobust mKRAS-specific T cell responses were observed... ► Artikel lesen | |
| 12.08.25 | Elicio Therapeutics Inc.: Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease ("MRD") Positive, Adjuvant-Stage Patients | 210 | GlobeNewswire (Europe) | At extended median follow-up of 19.7 months, median overall survival ("OS") increased from 16.33 to 28.94 months Clinical efficacy correlated with the magnitude of T cell responses specific to mutant-KRAS... ► Artikel lesen | |
| 12.08.25 | Elicio Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 08.08.25 | Elicio Therapeutics GAAP EPS of -$0.66 | 2 | Seeking Alpha | ||
| 07.08.25 | Elicio Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 07.08.25 | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates | 319 | GlobeNewswire (Europe) | Recent positive recommendation by the Independent Data Monitoring Committee ("IDMC") to continue ELI-002 7P randomized Phase 2 study in pancreatic cancer without modifications to final analysis Event-driven... ► Artikel lesen | |
| 05.08.25 | Elicio Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NANOREPRO | 1,530 | +0,66 % | NanoRepro: Zwei Aufsichtsräte treten zurück | Nachdem NanoRepro am Freitag das Verlangen der HWT invest Aktiengesellschaft auf Einberufung einer außerordentlichen Hauptversammlung publik gemacht hat, sind nun zwei Aufsichtsräte zurückgetreten.... ► Artikel lesen | |
| OCUGEN | 1,287 | 0,00 % | Ocugen Provides Business Update with Third Quarter 2025 Financial Results | Phase 2/3 OCU410ST GARDian3 pivotal confirmatory trial is progressing toward 1H 2027 Biologics License Application (BLA) filing with 50% enrollment completed to date European Medicines Agency (EMA)... ► Artikel lesen | |
| VIKING THERAPEUTICS | 27,555 | +1,47 % | Lilly und Viking Therapeutics abgestraft: Wegovy als Pille zerlegt den Markt - Novo-Aktie haussiert | © Foto: Steffen Trumpf/dpaDer Marktstart der Wegovy-Pille bringt Bewegung in den GLP-1-Sektor. Während Novo profitiert, machen Investoren bei Wettbewerbern Kasse. Novo Nordisk hat in den USA die Wegovy-Tablette... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,540 | -4,35 % | COSCIENS Biopharma Inc. Announces Leadership Change | TORONTO, ONTARIO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) ("COSCIENS" or the "Company"), a life science company focused on natural ingredients and pharmaceutical... ► Artikel lesen | |
| SCORPIUS | 0,070 | 0,00 % | Tivic Acquires Scorpius Manufacturing Assets And Secures More Than $90 Million Financing | ||
| BIOCRYST PHARMACEUTICALS | 6,360 | -2,57 % | BIOCRYST PHARMACEUTICALS INC - 8-K, Current Report | ||
| IBIO | 2,300 | +13,86 % | iBio announces private placement financing to raise ~$26M | ||
| VAXART | 0,600 | +46,34 % | Vaxart, Inc.: Vaxart to Participate in the Global BioInnovation Forum on January 13, 2026 | ||
| REDHILL BIOPHARMA | 1,275 | -3,41 % | What's Going On With Redhill Biopharma Stock On Tuesday? | ||
| ARBUTUS BIOPHARMA | 3,978 | -0,45 % | Arbutus Biopharma Corporation: Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March 2026;Favorable claim construction ruling in Pfizer-BioNTech... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 2,730 | +0,55 % | Zukunft der Krebstherapie: Warum diese NASDAQ-Aktie jetzt im Januar eine außergewöhnliche Einstiegschance bietet | ||
| MANNKIND | 4,986 | -2,58 % | MannKind Provides Business Updates and 2026 Growth Drivers | DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through... ► Artikel lesen | |
| ALDEYRA | 3,513 | -2,20 % | Aldeyra Therapeutics, Inc.: Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London | Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced... ► Artikel lesen | |
| TRAWS PHARMA | 1,370 | -2,84 % | Traws Pharma, Inc.: Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients | Ratutrelvir shows a differentiated profile versus PAXLOVID with fewer adverse events and no viral rebounds Activity shown in Paxlovid- -ineligible patients, representing a significant population with... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,462 | +10,18 % | Coherus BioSciences: Aktie legt nach Veröffentlichung von Daten zu CCR8-Antikörper zu |
ELICIO THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 7,100 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELICIO THERAPEUTICS INC finden Sie auf Wallstreet Online.